Amino.Desk

P21 (P021)

Updated Nov 17, 2026 · Clinical review: pending

P21, also written P021, is a small designed compound based on a nerve growth factor called CNTF. It is sold as a brain-repair and memory peptide. All of its evidence is in mice.

What it is

Researchers took the active fragment of CNTF, shortened it to four amino acids, and attached a carbon cage called adamantane to help it reach the brain. Sellers often describe it as a fragment of Cerebrolysin. It is a separate designed compound. It is also unrelated to the cell-cycle protein called p21.

What the evidence shows

In mice, including models of Alzheimer's disease, it raised a brain growth factor, increased the birth of new neurons and reduced tau pathology. Those results come almost entirely from the inventor's group, whose lead scientist co-founded the company commercializing it.

One independent assessment reports that the single outside attempt to reproduce the growth-factor effect in animals failed. No human trial exists.

Legal status

Reported dosing

We do not publish a protocol for this compound.

No dose has been established in people.

Safety

Common questions

Is P21 the same as Cerebrolysin?

No. It is a designed fragment of the growth factor CNTF, often marketed alongside Cerebrolysin.

Has P21 been tested in humans?

No. All of the evidence is from mice and cells.

Is P21 the same as the p21 protein?

No. They share a label and nothing else.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy